SEC Info - Allscripts Healthcare Solutions, Inc. - ‘10-Q’ for 6/30/22

SEC Info℠

Home

Help

Please Sign In

Allscripts Healthcare Solutions, Inc. – ‘10-Q’ for 6/30/22 – ‘R15’

On: Monday, 8/8/22, at 4:01pm ET · For: 6/30/22 · Accession #: 950170-22-15497 · File #: 1-35547

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/08/22  Allscripts Healthcare Soluti… Inc 10-Q        6/30/22  104:19M                                    Donnelley … Solutions/FA

Quarterly Report — Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   5.02M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     35K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     35K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     32K 
10: R1          Document and Entity Information                     HTML     84K 
11: R2          Consolidated Balance Sheets (Unaudited)             HTML    167K 
12: R3          Consolidated Balance Sheets (Unaudited)             HTML     57K 
                (Parenthetical)                                                  
13: R4          Consolidated Statements of Operations (Unaudited)   HTML    160K 
14: R5          Consolidated Statements of Comprehensive Income     HTML     66K 
                (Loss) (Unaudited)                                               
15: R6          Consolidated Statements of Stockholders' Equity     HTML    158K 
                (Unaudited)                                                      
16: R7          Consolidated Statements of Stockholders Equity      HTML     31K 
                (Parenthetical)                                                  
17: R8          Consolidated Statements of Cash Flows (Unaudited)   HTML    150K 
18: R9          Basis of Presentation and Significant Accounting    HTML     45K 
                Policies                                                         
19: R10         Revenue from Contracts with Customers               HTML    215K 
20: R11         Accounts Receivable                                 HTML     54K 
21: R12         Leases                                              HTML    136K 
22: R13         Business Combinations and Divestitures              HTML     89K 
23: R14         Fair Value Measurements and Long-term Investments   HTML    187K 
24: R15         Stockholders' Equity                                HTML    155K 
25: R16         Earnings (Loss) Per Share                           HTML    233K 
26: R17         Goodwill and Intangible Assets                      HTML    162K 
27: R18         Debt                                                HTML    210K 
28: R19         Income Taxes                                        HTML     76K 
29: R20         Derivative Financial Instruments                    HTML    157K 
30: R21         Accumulated Other Comprehensive Loss                HTML    280K 
31: R22         Contingencies                                       HTML     41K 
32: R23         Discontinued Operations                             HTML    357K 
33: R24         Business Segments                                   HTML    142K 
34: R25         Supplemental Disclosures                            HTML     66K 
35: R26         Basis of Presentation and Significant Accounting    HTML     69K 
                Policies (Policies)                                              
36: R27         Revenue from Contracts with Customers (Tables)      HTML    202K 
37: R28         Accounts Receivable (Tables)                        HTML     54K 
38: R29         Leases (Tables)                                     HTML    135K 
39: R30         Business Combinations and Divestitures (Tables)     HTML     76K 
40: R31         Fair Value Measurements and Long-term Investments   HTML    181K 
                (Tables)                                                         
41: R32         Stockholders' Equity (Tables)                       HTML    139K 
42: R33         Earnings (Loss) Per Share (Tables)                  HTML    233K 
43: R34         Goodwill and Intangible Assets (Tables)             HTML    165K 
44: R35         Debt (Tables)                                       HTML    159K 
45: R36         Income Taxes (Tables)                               HTML     63K 
46: R37         Derivative Financial Instruments (Tables)           HTML    153K 
47: R38         Accumulated Other Comprehensive Loss (Tables)       HTML    280K 
48: R39         Discontinued Operations (Tables)                    HTML    356K 
49: R40         Business Segments (Tables)                          HTML    133K 
50: R41         Supplemental Disclosures (Tables)                   HTML     65K 
51: R42         Basis of Presentation and Significant Accounting    HTML     69K 
                Policies - Additional Information (Detail)                       
52: R43         Revenue from Contracts with Customers - Additional  HTML     45K 
                Information (Detail)                                             
53: R44         Revenue from Contracts with Customers - Summary of  HTML     44K 
                Revenue Recognized on Various Performance                        
                Obligations and Elected Accounting Expedients                    
                (Detail)                                                         
54: R45         Revenue from Contracts with Customers - Summary of  HTML     54K 
                Revenue by Type and Nature of Revenue Stream by                  
                Reportable Segments (Detail)                                     
55: R46         Revenue from Contracts with Customers - Summary of  HTML     40K 
                Changes in Estimate of Credit Losses for Contract                
                Assets (Details)                                                 
56: R47         Accounts Receivable - Schedule of Changes in        HTML     38K 
                Estimate of Credit Losses for Trade Accounts                     
                Receivable (Detail)                                              
57: R48         Leases - Additional Information (Detail)            HTML     37K 
58: R49         Leases - Summary of Operating Costs Associated      HTML     37K 
                with Leased Assets (Detail)                                      
59: R50         Leases - Supplemental Cash Flow Information for     HTML     34K 
                Operating Leases (Detail)                                        
60: R51         Leases - Summary of Balance Sheet Location and      HTML     40K 
                Balances for Operating Leases (Detail)                           
61: R52         Leases - Summary of Future Maturities of Lease and  HTML     51K 
                Non-Lease Components (Detail)                                    
62: R53         Business Combinations and Divestitures -            HTML     91K 
                Additional Information (Detail)                                  
63: R54         Business Combinations and Divestitures - Schedule   HTML     53K 
                of Assets Acquired and Liabilities Assumed                       
                (Detail)                                                         
64: R55         Business Combinations and Divestitures - Schedule   HTML     42K 
                of Acquired Intangible Assets Amortization                       
                (Detail)                                                         
65: R56         Fair Value Measurements and Long-term Investments   HTML     59K 
                - Summary of Financial Assets and Liabilities                    
                Measured at Fair Value on Recurring Basis (Detail)               
66: R57         Fair Value Measurements and Long-term Investments   HTML     37K 
                - Summary of Changes in Liability Measured at Fair               
                Value on Recurring Basis (Detail)                                
67: R58         Fair Value Measurements and Long-term Investments   HTML     48K 
                - Summary of Long-term Equity Investments Included               
                in Other Assets (Detail)                                         
68: R59         Fair Value Measurements and Long-term Investments   HTML     41K 
                - Additional Information (Detail)                                
69: R60         Stockholders' Equity - Additional Information       HTML     66K 
                (Detail)                                                         
70: R61         Stockholders' Equity - Stock-Based Compensation     HTML     44K 
                Expense (Detail)                                                 
71: R62         Stockholders' Equity - Stock-Based Awards Granted   HTML     43K 
                (Detail)                                                         
72: R63         Earnings (Loss) Per Share - Calculations of         HTML     98K 
                Earnings (Loss) Per Share (Detail)                               
73: R64         Earnings (Loss) Per Share - Anti-Dilutive Stock     HTML     32K 
                Options, Restricted Stock Unit Awards and Warrants               
                Excluded from Computation of Diluted Earnings                    
                (Loss) Per Share (Detail)                                        
74: R65         Goodwill and Intangible Assets - Goodwill and       HTML     50K 
                Intangible Assets (Detail)                                       
75: R66         Goodwill and Intangible Assets - Changes in         HTML     42K 
                Carrying Amount of Goodwill (Detail)                             
76: R67         Goodwill and Intangible Assets - Additional         HTML     32K 
                Information (Detail)                                             
77: R68         Debt - Debt Outstanding Excluding Lease             HTML     43K 
                Obligations (Detail)                                             
78: R69         Debt - Debt Outstanding Excluding Lease             HTML     43K 
                Obligations (Parenthetical) (Detail)                             
79: R70         Debt - Interest Expense (Detail)                    HTML     41K 
80: R71         Debt - Interest Expense Related to 0.875%           HTML     40K 
                Convertible Senior Notes (Detail)                                
81: R72         Debt - Additional Information (Detail)              HTML    100K 
82: R73         Debt - Summary of Future Debt Payment Obligations   HTML     54K 
                (Detail)                                                         
83: R74         Debt - Summary of Future Debt Payment Obligations   HTML     33K 
                (Parenthetical) (Detail)                                         
84: R75         Income Taxes - Effective Tax Rates (Detail)         HTML     41K 
85: R76         Income Taxes - Additional Information (Detail)      HTML     45K 
86: R77         Derivative Financial Instruments - Fair Value and   HTML     43K 
                Balance Sheet Locations (Detail)                                 
87: R78         Derivative Financial Instruments - Additional       HTML     45K 
                Information (Detail)                                             
88: R79         Derivative Financial Instruments - Derivatives      HTML     45K 
                Instruments Designated as Cash Flow Hedges                       
                (Detail)                                                         
89: R80         Accumulated Other Comprehensive Loss - Components   HTML     66K 
                of Accumulated Other Comprehensive Loss (Detail)                 
90: R81         Accumulated Other Comprehensive Loss - Components   HTML     33K 
                of Accumulated Other Comprehensive Loss                          
                (Parenthetical) (Detail)                                         
91: R82         Accumulated Other Comprehensive Loss - Income Tax   HTML     79K 
                Effects Related to Components of Other                           
                Comprehensive Income (Loss) (Detail)                             
92: R83         Contingencies - Additional Information (Detail)     HTML     47K 
93: R84         Discontinued Operations - Additional Information    HTML     36K 
                (Detail)                                                         
94: R85         Discontinued Operations - Summary of Major Classes  HTML    117K 
                of Assets and Liabilities as Reported on                         
                Consolidated Balance Sheets (Detail)                             
95: R86         Discontinued Operations - Summary of Major Classes  HTML     37K 
                of Assets and Liabilities as Reported on                         
                Consolidated Balance Sheets (Parenthetical)                      
                (Detail)                                                         
96: R87         Discontinued Operations - Summary of Major Income   HTML     90K 
                and Expense Line Items Reported in Consolidated                  
                Statements of Operations (Detail)                                
97: R88         Business Segments - Additional Information          HTML     35K 
                (Detail)                                                         
98: R89         Business Segments - Revenues and Income (Loss)      HTML     53K 
                from Operations Related to Segment Within                        
                Reconciliation to Consolidated Amounts (Detail)                  
99: R90         Supplemental Disclosures - Supplemental             HTML     43K 
                Disclosures (Detail)                                             
102: XML         IDEA XML File -- Filing Summary                      XML    201K  
100: XML         XBRL Instance -- mdrx-20220630_htm                   XML   5.50M  
101: EXCEL       IDEA Workbook of Financial Reports                  XLSX    190K  
 7: EX-101.CAL  XBRL Calculations -- mdrx-20220630_cal               XML    281K 
 5: EX-101.DEF  XBRL Definitions -- mdrx-20220630_def                XML   1.01M 
 8: EX-101.LAB  XBRL Labels -- mdrx-20220630_lab                     XML   1.83M 
 9: EX-101.PRE  XBRL Presentations -- mdrx-20220630_pre              XML   1.45M 
 6: EX-101.SCH  XBRL Schema -- mdrx-20220630                         XSD    257K 
103: JSON        XBRL Instance as JSON Data -- MetaLinks              569±   936K  
104: ZIP         XBRL Zipped Folder -- 0000950170-22-015497-xbrl      Zip    473K

‘R15’ — Stockholders’ Equity

This is an IDEA Financial Report. [ Alternative Formats ]

Stockholders' Equity

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Stockholders' Equity

7. Stockholders' Equity

Stock-based Compensation Expense

Stock-based compensation expense recognized during the three and six months ended June 30, 2022 and 2021 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three and six months ended June 30, 2022 and 2021.


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Cost of revenue:
Provider	$	221	$	220	$	538	$	496
Payer & Life Sciences		37		49		25		106
Total cost of revenue		258		269		563		602
Selling, general and administrative expenses		8,309		2,335		13,798		4,888
Research and development		596		938		1,726		2,006
Total stock-based compensation expense	$	9,163	$	3,542	$	16,087	$	7,496

Allscripts Long-Term Incentive Plan

We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved.

The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the six months ended June 30, 2022 and 2021.

We granted stock-based awards as follows:


	Three Months Ended June 30, 2022				Six Months Ended June 30, 2022
			Weighted-Average				Weighted-Average
			Grant Date				Grant Date
(In thousands, except per share amounts)	Shares		Fair Value		Shares		Fair Value
Service-based restricted stock units		1,221	$	18.41		1,246	$	18.44
Performance-based restricted stock units with a service condition		243	$	18.56		243	$	18.56
Market-based restricted stock units with a service condition		258	$	21.90		258	$	21.90
		1,722	$	18.95		1,747	$	18.97

During the six months ended June 30, 2022 and the year ended December 31, 2021, 2.5 million and 2.2 million shares of common stock, respectively, were issued in connection with the release of restrictions on stock awards.

Net Share-settlements

Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax, and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the six months ended June 30, 2022 and 2021 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the six months ended June 30, 2022 and 2021 were 1.3 million and 895 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting.

Stock Repurchases

On November 18, 2020, we announced that our Board of Directors approved a stock purchase program (the “2020 Program”) under which we may repurchase up to $300 million of our common stock through December 31, 2021. The 2020 Program replaced a previous program that was fully utilized. During the three and six months ended June 30, 2021, we repurchased 5.6 million shares of our common stock under the 2020 Program for a total of $101.5 million, net of commissions. This was inclusive of the 1.6 million shares we received at final settlement of the accelerated share repurchase program we entered into on November 30, 2020. Please refer to Part II, Item 8 of our Form 10-K for further details on the accelerated share repurchase program.

On May 26, 2021, we announced that our Board approved a stock purchase program (the “2021 Program”) under which we may repurchase up to $350 million of our common stock. The 2021 Program replaced the 2020 Program that was fully utilized and did not have a termination date. During the three months ended June 30, 2021, we repurchased 11.5 million shares of our common stock under the 2021 Program for a total of $202.9 million, net of commissions. This was inclusive of the 9.1 million shares we received at initial settlement of the accelerated share repurchase program we entered into on June 14, 2021. Please refer to Part II, Item 8 of our Form 10-K for further details on the accelerated share repurchase program.

On January 24, 2022, we announced that our Board of Directors approved a stock purchase program (the “2022 Program”) under which we may repurchase up to $250 million of our common stock, with no termination date. The 2022 Program replaced the 2021 Program that was fully utilized. During the three months ended June 30, 2022, we repurchased 5.5 million shares of our common stock under the 2022 Program for a total of $93.7 million, net of commissions. During the six months ended June 30, 2022, we repurchased 7.8 million shares of our common stock under the 2022 Program for a total of $143.4 million, net of commissions.

The approximate dollar value of shares of our common stock that may yet be purchased under the 2022 Program was $106.8 million as of June 30, 2022. Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

Filed on:	8/8/22
For Period end:	6/30/22
	1/24/22	8-K
	12/31/21	10-K, 10-K/A, 5
	6/30/21	10-Q
	6/14/21	4, 8-K
	5/26/21	8-K
	11/30/20	8-K
	11/18/20	4
		List all Filings

1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/05/22  Veradigm Inc.                     8-K:2,5,9   5/02/22   13:2.1M                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0000950170-22-015497 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)